Evidence map›Paper›PMID 30361849›Full record

ArticleInternal and emergency medicine2019

Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet's disease.

Giuseppe Lopalco, Vincenzo Venerito, Luca Cantarini, Giacomo Emmi, Domenico Prisco, Florenzo Iannone

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Internal and emergency medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Advances in the Treatment of Behcet's Disease.Current rheumatology reports · 2021
    Review
  3. Recent Insights into the Management of Behçet Syndrome.Journal of inflammation research · 2021
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Giuseppe Lopalco *Rheumatology Unit, Department of Emergency and Organ Transplantation, Polyclinic Hospital, Piazza G. Cesare 11, 70124, Bari, Italy. glopalco@hotmail.it.ORCID http://orcid.org/0000-0003-4524-9566
Vincenzo Venerito *Rheumatology Unit, Department of Emergency and Organ Transplantation, Polyclinic Hospital, Piazza G. Cesare 11, 70124, Bari, Italy.
Luca CantariniDepartment of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases, Behçet's Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, University of Siena, Siena, Italy.
Giacomo EmmiDepartment of Experimental and Clinical Medicine, University of Firenze, Florence, Italy.
Domenico PriscoDepartment of Experimental and Clinical Medicine, University of Firenze, Florence, Italy.
Florenzo IannoneRheumatology Unit, Department of Emergency and Organ Transplantation, Polyclinic Hospital, Piazza G. Cesare 11, 70124, Bari, Italy.
University of Florence · ITPolyclinic General Hospital · GRUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

TimeAdultBehcet SyndromeBiosimilar PharmaceuticalsFemaleHumansInfliximabMaleMiddle AgedPatient SafetyBiosimilar PharmaceuticalsInfliximab

Identifiers

PMID30361849
OpenAlexW2898403984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.